Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Koenraad Debackere | M | 63 |
Université Catholique de Louvain
| 29 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Steven de Gryze | M | - |
Université Catholique de Louvain
| 11 years |
Hans Louis Jos de Winter | M | - |
Silicos SA
Silicos SA Pharmaceuticals: MajorHealth Technology Silicos, founded in June 2005, is a chemo-informatics-based biotechnology company empowering proprietary multi-target virtual screening technologies for the discovery of novel and high-quality lead compounds for the treatment of a large variety of diseases, such as cancer, infectious diseases, central nervous system and immunodeficiency diseases. Silicos' proprietary virtual screening technology is based on a unique concept called Spectrophores™, which are descriptors representing all possible three-dimensional molecular properties involved in the binding of a drug to its receptor. Cosmos™ is Silicos' platform for the de novo design of new small molecules optimized towards one or multiple targets. | 7 years |
Marcos Stefan Kulka Kuperman | M | - |
Université Catholique de Louvain
| 5 years |
Kenneth Francken | M | - |
Université Catholique de Louvain
| 5 years |
Koen Vervaeke | M | - |
Université Catholique de Louvain
| 5 years |
Louvrier Pierre Michel | M | 51 |
Université Catholique de Louvain
| 5 years |
Jeroen van den Keybus | M | - |
Université Catholique de Louvain
| 5 years |
Piet Vanassche | M | - |
Université Catholique de Louvain
| 5 years |
Dieter Penninckx | M | - |
Université Catholique de Louvain
| 7 years |
Marcin Lukaszewicz | M | - |
Université Catholique de Louvain
| 5 years |
Tim Piessens | M | - |
Université Catholique de Louvain
| 5 years |
Bram de Muer | M | - |
Université Catholique de Louvain
| 5 years |
Marcin Ziemowit Lukaszewicz | M | 57 |
Université Catholique de Louvain
| 5 years |
Johan van den Bossche | M | - |
Silicos SA
Silicos SA Pharmaceuticals: MajorHealth Technology Silicos, founded in June 2005, is a chemo-informatics-based biotechnology company empowering proprietary multi-target virtual screening technologies for the discovery of novel and high-quality lead compounds for the treatment of a large variety of diseases, such as cancer, infectious diseases, central nervous system and immunodeficiency diseases. Silicos' proprietary virtual screening technology is based on a unique concept called Spectrophores™, which are descriptors representing all possible three-dimensional molecular properties involved in the binding of a drug to its receptor. Cosmos™ is Silicos' platform for the de novo design of new small molecules optimized towards one or multiple targets. | - |
Wim Claes | M | - |
Université Catholique de Louvain
| 5 years |
Nicolas Roberti de Winghe | M | - |
Université Catholique de Louvain
| 5 years |
Bart de Moor | M | 63 |
Silicos SA
Silicos SA Pharmaceuticals: MajorHealth Technology Silicos, founded in June 2005, is a chemo-informatics-based biotechnology company empowering proprietary multi-target virtual screening technologies for the discovery of novel and high-quality lead compounds for the treatment of a large variety of diseases, such as cancer, infectious diseases, central nervous system and immunodeficiency diseases. Silicos' proprietary virtual screening technology is based on a unique concept called Spectrophores™, which are descriptors representing all possible three-dimensional molecular properties involved in the binding of a drug to its receptor. Cosmos™ is Silicos' platform for the de novo design of new small molecules optimized towards one or multiple targets. | - |
Wilfried van Langenaeker | M | - |
Silicos SA
Silicos SA Pharmaceuticals: MajorHealth Technology Silicos, founded in June 2005, is a chemo-informatics-based biotechnology company empowering proprietary multi-target virtual screening technologies for the discovery of novel and high-quality lead compounds for the treatment of a large variety of diseases, such as cancer, infectious diseases, central nervous system and immunodeficiency diseases. Silicos' proprietary virtual screening technology is based on a unique concept called Spectrophores™, which are descriptors representing all possible three-dimensional molecular properties involved in the binding of a drug to its receptor. Cosmos™ is Silicos' platform for the de novo design of new small molecules optimized towards one or multiple targets. | 7 years |
Karim Lesina | M | 49 |
Université Catholique de Louvain
| 1 years |
Gustavo Francisco Petro Urrego | M | 64 |
Université Catholique de Louvain
| 1 years |
Arnaud Laviolette | M | 61 |
Université Catholique de Louvain
| 1 years |
Nico Verplancke | M | - |
Université Catholique de Louvain
| 1 years |
Vincent Theunissen | M | - |
Université Catholique de Louvain
| 1 years |
Koen Uyttenhove | M | 49 |
Université Catholique de Louvain
| 3 years |
Julien Pestiaux | M | 45 |
Université Catholique de Louvain
| 4 years |
Lynn Nicholson | F | - |
Université Catholique de Louvain
| 5 years |
Gunnar Stork | M | - |
Université Catholique de Louvain
| 1 years |
Thomas Ykman | M | - |
Université Catholique de Louvain
| 4 years |
Leen Deley | F | 52 |
Université Catholique de Louvain
| 4 years |
François-Myriam-J. Derbaix | M | - |
Université Catholique de Louvain
| 5 years |
Pierre Matthieu | M | - |
Université Catholique de Louvain
| 4 years |
Eduardo Trénova Celedón | M | - |
Université Catholique de Louvain
| 2 years |
Isabelle Peeters | F | - |
Université Catholique de Louvain
| 5 years |
Benoît Taymans | M | - |
Université Catholique de Louvain
| 3 years |
Alexia Bertrand | F | 45 |
Université Catholique de Louvain
| 3 years |
Anneleen Desmyter | F | 47 |
Université Catholique de Louvain
| 2 years |
Esteban Abad | M | - |
Université Catholique de Louvain
| 1 years |
Louvre Pierre | M | 51 |
Université Catholique de Louvain
| 1 years |
Quentin Adam | M | - |
Université Catholique de Louvain
| 5 years |
France de Sadeleer | M | 55 |
Université Catholique de Louvain
| 1 years |
Sandrine Anton | F | - |
Université Catholique de Louvain
| 1 years |
Serge de Bock | M | - |
Université Catholique de Louvain
| 4 years |
Koen Bruynseels | M | - |
Université Catholique de Louvain
| 3 years |
An Cloet | F | 53 |
Université Catholique de Louvain
| 1 years |
Bernardo Bortolotti | M | 56 |
Université Catholique de Louvain
| 3 years |
Frederic Albert G Lammens | M | - |
Université Catholique de Louvain
| 6 years |
Mohamed Abalhossain | M | - |
Université Catholique de Louvain
| 1 years |
Óscar Lillo | M | - |
Université Catholique de Louvain
| 4 years |
Antoine Vanderhulst | M | - |
Université Catholique de Louvain
| 5 years |
Alexis Bernard | M | 50 |
Université Catholique de Louvain
| 5 years |
Eric Conrads | M | - |
Université Catholique de Louvain
| 4 years |
Johan Camp | M | 44 |
Université Catholique de Louvain
| 1 years |
Zeger Debyser | M | - |
Université Catholique de Louvain
| 3 years |
Jochen Pflug | M | - |
Université Catholique de Louvain
| 1 years |
Mathieu Francois Pierre Pasture | M | - |
Université Catholique de Louvain
| 4 years |
Marc Mommaerts | M | - |
Silicos SA
Silicos SA Pharmaceuticals: MajorHealth Technology Silicos, founded in June 2005, is a chemo-informatics-based biotechnology company empowering proprietary multi-target virtual screening technologies for the discovery of novel and high-quality lead compounds for the treatment of a large variety of diseases, such as cancer, infectious diseases, central nervous system and immunodeficiency diseases. Silicos' proprietary virtual screening technology is based on a unique concept called Spectrophores™, which are descriptors representing all possible three-dimensional molecular properties involved in the binding of a drug to its receptor. Cosmos™ is Silicos' platform for the de novo design of new small molecules optimized towards one or multiple targets. | - |
Guy Mannaerts | M | - |
Silicos SA
Silicos SA Pharmaceuticals: MajorHealth Technology Silicos, founded in June 2005, is a chemo-informatics-based biotechnology company empowering proprietary multi-target virtual screening technologies for the discovery of novel and high-quality lead compounds for the treatment of a large variety of diseases, such as cancer, infectious diseases, central nervous system and immunodeficiency diseases. Silicos' proprietary virtual screening technology is based on a unique concept called Spectrophores™, which are descriptors representing all possible three-dimensional molecular properties involved in the binding of a drug to its receptor. Cosmos™ is Silicos' platform for the de novo design of new small molecules optimized towards one or multiple targets. | - |
Guy van den Mooter | M | - |
Université Catholique de Louvain
| 12 years |
Martinus Antonius Hendrikus Vogels | M | - |
Université Catholique de Louvain
| 3 years |
Luc Dehaspe | M | - |
Université Catholique de Louvain
| 3 years |
Armando Arrieta | M | - |
Université Catholique de Louvain
| 2 years |
Frédéric Adam | M | - |
Université Catholique de Louvain
| 4 years |
Ignace Lasters | M | - |
Université Catholique de Louvain
| - |
Stefano Quintini | M | - |
Université Catholique de Louvain
| 3 years |
Armando J. Arrieta M. | M | - |
Université Catholique de Louvain
| 2 years |
Peter van Overschee | M | - |
Université Catholique de Louvain
| 3 years |
Willem Frans Alfons van Twembeke | M | 59 |
Université Catholique de Louvain
| 2 years |
Matthias de Raeymaeker | M | 49 |
Université Catholique de Louvain
| 3 years |
Egied Octavius Verbeeck | M | 48 |
Université Catholique de Louvain
| 3 years |
Bertrand Désirand | M | - |
Université Catholique de Louvain
| 4 years |
Kristof Macours | M | 58 |
Université Catholique de Louvain
| 3 years |
Xavier Denis | M | 52 |
Université Catholique de Louvain
| 4 years |
Noël Jans | M | - |
Université Catholique de Louvain
| 1 years |
Sandrine Jacobs | F | 50 |
Université Catholique de Louvain
| 3 years |
Stéphanie Vanden Broecke | F | - |
Université Catholique de Louvain
| 1 years |
Peter Raeymaeckers | M | - |
Université Catholique de Louvain
| 4 years |
Dirk de Backer | M | 53 |
Université Catholique de Louvain
| 5 years |
Hans Keppens | M | - |
Université Catholique de Louvain
| 1 years |
John Eric F. P. C. Bertrand | M | 46 |
Université Catholique de Louvain
| 1 years |
Johannes Steensma | M | - |
Université Catholique de Louvain
| 3 years |
Yves Gonnissen | M | - |
Université Catholique de Louvain
| 1 years |
Jean Naveau | M | 70 |
Université Catholique de Louvain
| 2 years |
Jean-Claude Schmit | M | - |
Université Catholique de Louvain
| 3 years |
Grégoire Dallemagne | M | 51 |
Université Catholique de Louvain
| 4 years |
Jean-Pol Detiffe | M | 51 |
Université Catholique de Louvain
| 1 years |
Frederik Loeckx | M | - |
Université Catholique de Louvain
| 1 years |
Anja Maes | F | - |
Université Catholique de Louvain
| 4 years |
Emmanuel Bracke | M | - |
Université Catholique de Louvain
| 4 years |
Tine de Ryck | F | 43 |
Université Catholique de Louvain
| 4 years |
Olivier Banneux | M | - |
Université Catholique de Louvain
| 5 years |
Statistics
Country | Connections | % of total |
---|---|---|
Belgium | 91 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Gert Adam Irma Thijs
- Personal Network